Insider

Pfizer Inc

PFE Health Care · 2 analyses · 15 expectations tracked

Pfizer reported $16.6B in revenue (-0.4% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 15 open management expectations for this company. Its latest periodic filing added 25 new risk factors.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Key figures

From the 10-Q for the period ended September 27, 2026, filed November 3, 2026. SEC

LatestEarlierChange
Revenue quarter$16.6B$16.7B-0.4%
Net income quarter$3.2B$3.5B-8.4%
Diluted EPS quarter$0.56$0.62-9.7%
Dividends per share quarter$0.00$0.00—
Operating cash flow year to date$8.8B$6.4B+38.8%
Cash and cash equivalents balance$1.8B$1.1B+59.7%
Long-term debt balance$60B$61.6B-2.7%

Next results expected around February 2, 2027 (estimate: the quarter ending about December 27, 2026 plus the 37 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

17.8Q4 '24*13.7Q1 '2514.7Q2 '2516.7Q3 '2517.6Q4 '25*14.5Q1 '2615Q2 '2616.6Q3 '26
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Pfizer Inc PFE$16.6B-0.4%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The company does not currently anticipate the availability of raw materials to have a significant impact on operations in 2026.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company expects an unfavorable revenue impact of approximately $1.1 billion in 2026 due to patent-based or regulatory exclusivity expiries.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company anticipates a significant reduction of revenue from patent-based or regulatory exclusivity expiries between 2026 and 2030.

    Said November 3, 2026 · Period named: 2026 through 2030 · Source · Our article

    Not yet checked against later reports.

  • The company anticipates an unfavorable revenue impact of approximately $1.1 billion due to generic and biosimilar competition.

    Said November 3, 2026 · Period named: full-year 2026 · Source · Our article

    Not yet checked against later reports.

  • The company does not expect a material, incremental impact from the IRA Medicare Part D Redesign in 2026 versus the 2025 baseline.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Pfizer expects to incur one-time costs of approximately $2.0 billion to achieve the additional savings from the Realigning Our Cost Base Program through 2029.

    Said November 3, 2026 · Period named: through 2029 · Source · Our article

    Not yet checked against later reports.

Show all (15)
  • Pfizer expects its Manufacturing Optimization Program to deliver additional anticipated savings of approximately $1.5 billion from 2027 through 2029.

    Said November 3, 2026 · Period named: 2027 through 2029 · Source · Our article

    Not yet checked against later reports.

  • Full-year 2026 financial guidance does not assume the completion of any business development transactions not completed as of November 3, 2026.

    Said November 3, 2026 · Period named: full-year 2026 · Source · Our article

    Not yet checked against later reports.

  • Guidance for Adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.74 billion shares and no share repurchases.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Pfizer expects one-time costs to achieve savings for the Manufacturing Optimization Program to total approximately $4.0 billion, with about 60% being non-cash expenditures, incurred through 2029.

    Said November 3, 2026 · Period named: through 2029 · Source · Our article

    Not yet checked against later reports.

  • Current financial guidance does not anticipate any share repurchases in 2026.

    Said November 3, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Full-year 2026 Adjusted diluted EPS guidance raised and narrowed to a range of $2.95 to $3.05.

    Said November 3, 2026 · Period named: full-year 2026 · Source · Our article

    Not yet checked against later reports.

  • The HHS 340B pilot program is expected to begin in January 2027 and include Eliquis, Ibrance and Xtandi.

    Said November 3, 2026 · Period named: January 2027 · Source · Our article

    Not yet checked against later reports.

  • Full-year 2026 Revenue guidance raised to a range of $62.0 to $64.0 billion.

    Said November 3, 2026 · Period named: full-year 2026 · Source · Our article

    Not yet checked against later reports.

  • Effective tax rate on Adjusted income is expected to be approximately 15.0%.

    Said November 3, 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed November 3, 2026 compared with the 10-Q filed August 4, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (25)

  • (MILLIONS) | | Sept. 27, 2026 | | Sept. 28, 2025 | | Sept. 27, 2026 | | Sept. 28, 2025 | | Sept. 27, 2026 | | Sept. 28, 2025 | | % Change
  • | | 300 | | | 344 | | | 56 | | | 92 | | | 244 | | | 253 | | | (13) | | | (39) | | | (3)
  • | | 962 | | | 966 | | | 228 | | | 282 | | | 735 | | | 684 | | | — | | (19) | | | 7

Dropped (15)

  • Part D benefit design (IRA Medicare Part D Redesign), which took effect beginning in 2025. We do not expect a material, incremental impact from the IRA Medicare Part D Redesign in 2026 versus the baseline set in 2025. In addition, changes to the Medicaid Drug Rebate Program or the 340B Program, including legal or legislative developments at the federal or state level with respect to the 340B Program, could have a material impact on our business. See the Item 1. Business––Pricing Pressures and Managed Care Organizations and ––Government Regulation and Price Constraints and the Item 1A. Risk…
  • | | 373 | | | 348 | | | 67 | | | 101 | | | 306 | | | 247 | | | 7 | | | (34) | | | 24
  • | | 662 | | | 622 | | | 172 | | | 190 | | | 490 | | | 432 | | | 7 | | | (10) | | | 14

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 3, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock521,032,629$14,859,850,573-1.6%Q3 2026
State Street309,573,847$8,829,046,116+0.8%Q3 2026
Geode Capital Management137,506,393$3,907,781,638+1.6%Q3 2026
Norges Bank (Norway's sovereign fund)61,505,586$1,481,054,511—Q2 2026
Fidelity (FMR)18,004,331$513,483,530+16.9%Q3 2026
D. E. Shaw & Co.16,584,679$472,995,045+206.3%Q3 2026
Wellington Management11,244,339$320,688,548-59.6%Q3 2026
Two Sigma Investments6,419,852$183,094,179+1,843.6%Q3 2026
Citadel Advisors4,741,501$135,227,609-23.4%Q3 2026
Renaissance Technologies1,989,077$56,728,501—Q3 2026
Millennium Management1,739,069$49,598,248+212.7%Q3 2026
Bridgewater Associates477,929$13,630,535+165.4%Q3 2026
T. Rowe Price9,266,055$264,269-36.2%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.